Protagonist Therapeutics, Inc. (PTGX)
NASDAQ: PTGX · Real-Time Price · USD
89.65
+2.32 (2.66%)
At close: Dec 5, 2025, 4:00 PM EST
89.00
-0.65 (-0.73%)
After-hours: Dec 5, 2025, 6:37 PM EST
Protagonist Therapeutics Stock Forecast
Stock Price Forecast
According to 9 professional analysts, the 12-month price target for Protagonist Therapeutics stock ranges from a low of $73 to a high of $102. The average analyst price target of $86.44 forecasts a -3.58% decrease in the stock price over the next year.
Price Target: $86.44 (-3.58%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Protagonist Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 4 | 4 | 4 | 4 |
| Buy | 4 | 4 | 4 | 5 | 5 | 5 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 8 | 9 | 9 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citigroup | Citigroup | Strong Buy Maintains $96 → $98 | Strong Buy | Maintains | $96 → $98 | +9.31% | Nov 10, 2025 |
| JP Morgan | JP Morgan | Buy Maintains $68 → $81 | Buy | Maintains | $68 → $81 | -9.65% | Nov 7, 2025 |
| Barclays | Barclays | Buy Maintains $72 → $88 | Buy | Maintains | $72 → $88 | -1.84% | Nov 7, 2025 |
| Citizens | Citizens | Buy Maintains $69 → $102 | Buy | Maintains | $69 → $102 | +13.78% | Nov 7, 2025 |
| Truist Securities | Truist Securities | Strong Buy Maintains $76 → $88 | Strong Buy | Maintains | $76 → $88 | -1.84% | Oct 28, 2025 |
Financial Forecast
Revenue This Year
66.12M
from 434.43M
Decreased by -84.78%
Revenue Next Year
262.15M
from 66.12M
Increased by 296.47%
EPS This Year
-1.97
from 4.23
EPS Next Year
-0.65
from -1.97
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 271.9M | 551.3M | ||||
| Avg | 66.1M | 262.2M | ||||
| Low | 37.8M | 19.6M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -37.4% | 733.7% | ||||
| Avg | -84.8% | 296.5% | ||||
| Low | -91.3% | -70.4% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -1.32 | 5.29 | ||||
| Avg | -1.97 | -0.65 | ||||
| Low | -2.28 | -2.31 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.